Edition:
United Kingdom

People: Zealand Pharma A/S (ZEAL.OQ)

ZEAL.OQ on NASDAQ Stock Exchange Global Select Market

13.00USD
19 Oct 2018
Change (% chg)

$-0.93 (-6.68%)
Prev Close
$13.93
Open
$13.73
Day's High
$13.73
Day's Low
$13.00
Volume
1,622
Avg. Vol
3,635
52-wk High
$18.91
52-wk Low
$12.01

Nicklasson, Alf 

Dr. Alf Gunnar Martin (Martin) Nicklasson, Ph.D. has been Independent Chairman of the Board at Zealand Pharma A/S since April 21, 2015. Martin has held broad-based executive experience from positions in European pharmaceutical and biotech companies. He held executive vice president positions at AstraZeneca PLC and has served as President and CEO of Biovitrum AB and Swedish Orphan Biovitrum AB. Prior to this, he held a number of leadership positions at AB Astra and Kabi Pharmacia AB. Martin Nicklasson is chairman of the board of Orexo AB and Kymab Ltd., as well as Board Member of Basilea Pharmaceutica Ltd. He is a certified pharmacist and holds a Ph.D. in Pharmaceutical Technology from the Uppsala University, where he is Associate Professor at the Department of Pharmaceutics.

Basic Compensation

Total Annual Compensation, DKK 650,000
Restricted Stock Award, DKK --
Long-Term Incentive Plans, DKK --
All Other, DKK --
Fiscal Year Total, DKK 650,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Alf Nicklasson

650,000

Britt Meelby Jensen

11,078,000

Rosemary Crane

400,000

Mats Blom

6,405,000

Ivan Moeller

--

Andrew Parker

--
As Of  31 Dec 2017